Atea Pharmaceuticals, Inc. (NasdaqGS: AVIR)
Health Care · Pharmaceuticals · US
$5.09
-1.17% today · +64.5% 1Y
Atea Pharmaceuticals, Inc. (NasdaqGS: AVIR) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $413.05M and employs 55 people.
Over the last twelve months the share price has gained 64.5%, trading between 2.87 and 6.45.
Tweenvest scores Atea Pharmaceuticals, Inc. across four factors: quality 81/100, value 65/100. Its strongest factor is quality.
AVIR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $413.05M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.10
- Dividend yield
- —
- Beta (5Y)
- 0.39
- 52-week high
- $6.45
- 52-week low
- $2.87
- Avg volume (3M)
- —
- Shares outstanding
- 80.20M
- Employees
- 55
- Next earnings
- —
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- ISIN
- US04683R1068
- Founded
- 2012
- Listed since
- Oct 30, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Gufic Biosciences LimitedBSE: 509079 | $419.45M | Rs404.80 | -3.20% |
| Renata PLCDSE: RENATA | $418.98M | Tk449.90 | +0.27% |
| Hangzhou TianMuShan Pharmaceutical Enterprise Co.,LtdSHSE: 600671 | $416.71M | CN¥22.92 | +5.19% |
| Chengdu huasun technology group Inc. , LTD.SZSE: 000790 | $413.45M | CN¥4.44 | +0.45% |
| JCR Pharmaceuticals Co., Ltd.TSE: 4552 | $407.69M | ¥529.00 | +9.52% |
| Allergy Therapeutics plcAIM: AGY | $398.04M | £0.05 | 0.00% |
| Shandong Sito Bio-technology Co., Ltd.SZSE: 300583 | $394.52M | CN¥13.93 | +1.68% |
| Aarti Drugs LimitedBSE: 524348 | $389.58M | Rs413.10 | -2.12% |
Figures last refreshed Oct 11, 2026.